Full text is available at the source.
Should We Stop Glucagon-Like Peptide-1 Receptor Agonists Before Surgical or Endoscopic Procedures? Balancing Limited Evidence With Clinical Judgment
Deciding Whether to Pause Glucagon-Like Peptide-1 Medicines Before Surgery or Procedures with Limited Evidence
AI simplified
Abstract
Discontinuing glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment before surgery may worsen glycemic control in patients with diabetes.
- Current recommendations to stop GLP-1 RA agents before surgery are based on concerns about pulmonary aspiration but lack sufficient scientific evidence.
- There is a need for observational and prospective studies to assess the risk of pulmonary aspiration in patients using GLP-1 RA.
- Understanding the short-term effects of discontinuing GLP-1 RA on glycemic control is crucial for managing patients with diabetes during elective surgeries.
- An alternative multidisciplinary approach is suggested for managing patients undergoing elective surgery while waiting for more safety data.
AI simplified